Assessment of Hematopoietic Recovery Following Chemotherapy for Non-Hodgkin's Lymphoma

Assessment of Hematopoietic Recovery Following Chemotherapy for Non-Hodgknin's Lymphoma

Status

Terminated

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00775957

Enrollment

Registered

2008-10-20

Start date

2008-10-31

Completion date

Unknown

Last updated

2010-09-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-Hodgkin's Lymphoma

Brief summary

A study to determine the accuracy of FLT-PET in quantifying tumor cell proliferation at the initial staging of patients with Non-Hodgkin's Lymphoma in comparison wit the gold standard FDG-PET.

Detailed description

The first primary objective reflects a necessary and preliminary requirement: to reproduce published results and validate the use of FLT-PET. In this study, 35 patients will be selected to undergoing imaging with both FLT and FDG PET.

Interventions

PROCEDUREFLT-PET scan

imaging scan

PROCEDUREFDG-PET scan

imaging scan

Study design

Observational model

CASE_CONTROL

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* 18 years or older * Women must not be pregnant or breast feeding * Histologic diagnosis of non-Hodgkin's lymphoma (any stage) * Must undergo treatment with chemotherapy and/or radiotherapy

Exclusion criteria

* May not have received previous therapy with radiopharmaceuticals * May not have received prior therapy with cytotoxic chemotherapy and/or monoclonal antibodies

Design outcomes

Primary

Measure	Time frame
Staging and ReStaging scans	after hematopoetic recovery

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026